15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC

Element Squared LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,051 shares of the biotechnology company’s stock, valued at approximately $2,649,000. Biogen makes up approximately 1.4% of Element Squared LLC’s portfolio, making the stock its 15th largest position.

A number of other institutional investors and hedge funds also recently bought and sold shares of BIIB. Advisory Services Network LLC boosted its holdings in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares during the last quarter. CVA Family Office LLC increased its holdings in shares of Biogen by 18.1% during the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares during the last quarter. Davis Investment Partners LLC increased its holdings in shares of Biogen by 1.7% during the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after buying an additional 71 shares during the last quarter. TD Private Client Wealth LLC raised its position in shares of Biogen by 22.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 76 shares during the period. Finally, CX Institutional raised its position in shares of Biogen by 6.1% during the 3rd quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 83 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

Shares of BIIB opened at $177.34 on Friday. The company has a market cap of $26.03 billion, a P/E ratio of 20.13, a PEG ratio of 2.37 and a beta of 0.16. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The firm’s 50 day moving average price is $186.60 and its 200 day moving average price is $171.35.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the firm posted $3.44 earnings per share. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BIIB shares. Citigroup increased their price objective on Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Barclays began coverage on Biogen in a report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price target for the company. Wolfe Research set a $231.00 price objective on Biogen in a research report on Monday, February 9th. Finally, Wedbush boosted their price objective on shares of Biogen from $187.00 to $191.00 and gave the company a “neutral” rating in a report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $208.31.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.